Evaxion Biotech A/S (NASDAQ:EVAX) Short Interest Up 709.3% in December

Evaxion Biotech A/S (NASDAQ:EVAX) was the recipient of a large increase in short interest in December. As of December 31st, there was short interest totalling 980,100 shares, an increase of 709.3% from the December 15th total of 121,100 shares. Based on an average daily volume of 335,500 shares, the short-interest ratio is presently 2.9 days.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a “buy” rating and issued a $70.00 target price on shares of Evaxion Biotech A/S in a report on Friday, November 1st.

Evaxion Biotech A/S Stock Down 14.8 %

Shares of EVAX traded down $0.56 during trading hours on Wednesday, reaching $3.22. The company’s stock had a trading volume of 336,227 shares, compared to its average volume of 84,532. The company has a 50 day moving average of $6.56 and a two-hundred day moving average of $11.86. The company has a quick ratio of 2.80, a current ratio of 1.00 and a debt-to-equity ratio of 7.99. The firm has a market cap of $18.90 million, a price-to-earnings ratio of -11.11 and a beta of -0.23. Evaxion Biotech A/S has a 1-year low of $3.17 and a 1-year high of $68.05.

Evaxion Biotech A/S (NASDAQ:EVAX) last announced its quarterly earnings data on Thursday, October 31st. The company reported ($0.20) EPS for the quarter, beating analysts’ consensus estimates of ($0.60) by $0.40. The company had revenue of $3.02 million for the quarter, compared to analysts’ expectations of $0.19 million. As a group, research analysts predict that Evaxion Biotech A/S will post -0.15 EPS for the current fiscal year.

Institutional Trading of Evaxion Biotech A/S

A hedge fund recently bought a new stake in Evaxion Biotech A/S stock. Invst LLC bought a new position in Evaxion Biotech A/S (NASDAQ:EVAX) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 54,000 shares of the company’s stock, valued at approximately $156,000. Invst LLC owned about 1.00% of Evaxion Biotech A/S at the end of the most recent reporting period. Institutional investors and hedge funds own 11.04% of the company’s stock.

About Evaxion Biotech A/S

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers.